title: Agomelatine: a review of adverse effects.
abstract: More pharmacovigilance data on agomelatine became available in 2012. The main sources of information were surveillance data from the French national monitoring system, EU periodic safety update reports (PSURs), and the European pharmacovigilance database. The principal adverse effects of agomelatine consist of hepatic, pancreatic, neuropsychiatric, muscular and cutaneous disorders. The harms associated with agomelatine, which has no proven efficacy in depression, clearly outweigh the benefits. Until regulatory agencies decide to withdraw agomelatine from the market, it is up to healthcare professionals to protect patients from this unnecessarily dangerous drug.
mesh_terms: D000081:Acetamides / Q000009:adverse effects* / Q000627:therapeutic use; D016907:Adverse Drug Reaction Reporting Systems; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy*; D005062:European Union; D006801:Humans; D044094:Receptors, Melatonin / Q000819:agonists; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D000928:Antidepressive Agents; D044094:Receptors, Melatonin; C084711:agomelatine; D009281:Naphthalenes